LONGEVITY with Nathalie Niddam #380: Detecting Potential Cancer With TEARS: The Surprising Future of Early Screening With Omid Moghadam
Oct 21, 2025
Omid Moghadam, a biotech entrepreneur and inventor focused on cancer screening, shares his innovative journey driven by personal stories of loss. He discusses how groundbreaking tear-based testing for breast cancer works, revealing that tears provide clearer signals than blood. Omid highlights the affordability of this approach and the role of AI in its development. He also touches on expanding screening to other cancers and the future of personalized radiopharmaceuticals, showcasing a vision for accessible, effective cancer diagnostics.
AI Snips
Chapters
Transcript
Episode notes
Screening Is A Risk-Stratification Tool
- Screening differs from diagnostics: screens flag possible disease and prompt further testing rather than give a binary answer.
- Effective screening casts a wide net to avoid missing cases, accepting more false positives as trade-off.
Act On A Positive Screen With Imaging Then Intervention
- If Aria flags you as clinically significant, get imaging promptly to rule in or out a tumor.
- If imaging is clear, consider functional medicine strategies to reduce inflammation and cancer risk.
Proteomics Enables Earlier Detection Than cfDNA
- DNA-based cfDNA tests detect formed tumors (mid-stage) while protein biomarkers can detect earlier disease signals.
- Funding favored DNA, but proteomics is gaining traction and may enable earlier detection.